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Abstract 
Millions of young women are rendered sterile by chemotherapy-associated oocyte loss. Recently some studies linked 
stem-cell transplantations to a spontaneous and unexplained return of ovarian function in some women rendered 
prematurely menopausal by high-dose chemotherapy or irradiation   when they undergo bone marrow transplantation as 
part of their treatment protocol. This study was designed to investigate the therapeutic potential of human umbilical cord 
blood CD34+ cells transplantation on cyclophosphamide-induced ovarian dysfunction in rats. In this paper; Twenty one 
Sprague-Dawly albino mature female rats were used in this study. Animals were randomly divided into three equal 
groups: group (1) was a normal control group, group (2) was the cyclophosphamide-treated group and    group (3) was 
the stem cells transplanted group after cyclophosphamide administration. Measurement of serum FSH and estradiol 
levels and histopathological examination of ovaries were done. The Results shows that the Human umbilical cord blood 
CD34+ cells transplantation significantly decreased the loss of ovarian follicles,   restored the folliculogenesis and had no 
significant effect on serum FSH or estradiol levels. The current study suggests that transplantation of human umbilical 
cord blood hematopoietic CD34+ cells into rats with cyclophosphamide-induced ovarian dysfunction improves ovarian 
folliculogenesis function with no significant effect on hormonal secretion function and further studies are required to 
clarify the role of stem cells transplantation as a cure for ovarian dysfunction. 
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1. Introduction: 
Each year millions of women undergo fertility treatments due to age-related loss of oocytes; these treatments offer only 
modest improvements in fertility. Furthermore, millions of young women are rendered sterile by chemotherapy-
associated oocyte loss [1]. 
Gonadal failure as a result of germ cell depletion can occur at any age, and from the effects of chemical cytotoxicity, 
disease and infection as well as genetic predisposition [2]. There are two basic categories of gonadal failure: one in 
which there are few to no remaining follicles, and in the second, there are an abundant number of follicles. In the first 
situation, the causes include genetic disorders, chemotherapy, radiation to the pelvic region, surgery, however, in most 
cases, the cause is unknown. In the second case, a frequent cause is autoimmune ovarian disease, which damages 
maturing follicles but leaves the primordial follicles intact. Currently, there are no proven treatments that restore normal 
functionality to a woman's ovaries [1]. 
One of the most devastating adverse effects of cancer treatments is damage to the reproductive system, which in young 
girls and women less than 40 years old is frequently associated with premature menopause and infertility [3]. With recent 
advances in cancer care, more and more young women can survive but suffer from infertility as a result of cancer 
treatment that had to be submitted [4]. Early loss of ovarian function has significant psychosocial sequelae and major 
health implications; nearly 2-fold age-specific increase in mortality rate has been reported [5]. A chemical exposure that 
is of direct human concern is cyclophosphamide, due to its wide use in chemotherapeutic regimens against cancer and 
autoimmune disorders [6].The reproductive outcomes of chemotherapy in women seem to be, in large part, a result of 
cytotoxic effects on oocytes housed within the ovaries and with near-universally accepted dogma that oocytes are 
endowed as a fixed and nonrenewing stockpile at birth, pathologic destruction of oocytes has been viewed as 
irreversible. Thus, experimental approaches aimed at sustaining fertility in female cancer survivors have been directed 
solely at preservation of existing oocytes [3]. 
There are a variety of methods to preserve fertility, as chemoprotection, ovariopexy, and some assisted reproductive 
technologies, although some of these are promising but still highly experimental techniques [4]. 
Recently some studies linked stem-cell transplantations to a spontaneous and unexplained return of ovarian function in 
some women rendered prematurely menopausal by high-dose chemotherapy or irradiation   when they undergo bone 
marrow transplantation as part of their treatment protocol [7,8,9]. These studies raise the possibility that, stem-cell 
transplantation could be considered as a viable therapeutic option to revive ovarian function and restore fertility in 
women after chemotherapy [3]. 
In recent years, human umbilical cord blood (HUCB) has emerged as an attractive tool for cell-based therapy. Although 
at present the clinical application of HUCB is limited to the fields of hematology and oncology, a rising number of 
studies show potential for further application in the treatment of non-hematopoietic diseases. HUCB, with its real 
abundance, simple collection procedure and no serious ethical dilemmas, represents a valuable alternative to the use of 
other stem cell sources [10]. 
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In our previous studies we found improvement after HUCB CD34+  cells transplantation in carbon tetrachloride-induced  
liver fibrosis in mice [11],  streptozotocin-induced diabetes in mice [12]  and diabetic nephropathy in rats [13].So this 
study was designed to investigate the therapeutic potential of HUCB CD34+ cells transplantation on cyclophosphamide-
induced ovarian dysfunction in rats. 
2. Materials & Methods 
2.1. Animals: Twenty one Sprague-Dawly albino mature female rats 3 months old and their weight range was 180 – 200 
g were used in this study. Animals were brought from the Ophthalmic Research Institute Center for experimental animals 
in Giza, were acclimatized for one week and kept with free access to standard pellet animal diet and tap water under 
controlled conditions of room temperature. 
Animals were randomly divided into three equal groups: 
Group (1):  this group was a normal control group.  
Group (2):this group was the cyclophosphamide-treated group and it was subjected to Induction of ovarian dysfunction 
with cyclophosphamide without any intervention.    
Group (3): this group was the stem cells transplanted group and it was subjected to: 
• Induction of ovarian dysfunction with cyclophosphamide. 
• Transplantation of 1 x 106 HUCB CD 34 + cells after the last injection of cyclophosphamide.2.2. Methods 
2.2.1. Type of the study:An experimental case- control study. 
2.2.2. Study site:This study was carried out in Suez Canal University, Faculty of Medicine, 
Physiology department, Stem Cell Unit. 
2.2.3. Induction of ovarian dysfunction:The rats in group 2 and 3 were injected (IP) with 50 mg/kg 
of  cyclophosphamide, as a loading dose followed by daily IP injection of 8 mg/kg cyclophosphamide for 
14 consecutive days [14]. Two rats were sacrificed at the end of this protocol for histopathological 
examination to confirm ovarian dysfunction but ovarian dysfunction was not confirmed in them so the daily 
injections of cyclophosphamide were extended for two weeks then two rats were sacrificed, and ovarian 
dysfunction wasconfirmed by histopathological examination. 
2.2.4. Collection and isolation of HUCB CD34+ cells:Sterilecollection tubes (50 ml), containing 5 
ml citrate phosphate dextrose adenine-1 (CPDA-1)asanticoagulant, were used for collection of the HUCB. 
Mononuclear cells were isolated by Ficoll-Hypaque density gradient centrifugation (Sigma Chemical Co., 
Egypt). Separation of CD34 positive progenitor cells was carried out with immunomagnetic separation 
technique by Dynal CD34+ progenitor cell selection system[12]. 
2.2.5. Transplantation of HUCB CD34+ cells:0.2 ml of phosphate buffer saline solution was added 
to the CD34+ cell pellet for injection in the rat tail vein in a dose of 1 X 106 cells/ rat in group (3) after the 
last cyclophosphamide injection. 0.2 ml of phosphate buffer saline were injected in the rat tail vein in 
groups (1) and (2) [12]. 
 Eight weeks after Transplantation of HUCB CD34+ cells, all rats were   anesthetized and blood collection 
from retro-orbital venous plexus was done for serum follicle-stimulating hormone(FSH) and estradiol 
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assays then both ovaries were removed for histopathology. 
2.2.6. Histopathology of the ovaries:The ovaries were collected. The rat ovaries were fixed in 4% 
formaldehyde, and paraffin-embedded sections were produced. The 4μm paraffin-embedded sections were 
rehydrated using xylene and a graded alcohol series and stained with hematoxylin and eosin (H&E).  
Histopathological examination was done by two professional  pathologists. 
2.2.7. Serum FSH and Estradiol assay:The serum was obtained by centrifugation (2400 rpm, for 
20 minutes at 4°C) and the concentrations of estradiol(E2), and FSH  were determined by (Vidas, 
Biomerieux). All samples were performed within the same assay to reduce interassay Variation. The 
respective intra-assay and interassay coefficients of variation (CVs) were as follows: E2 (4.2% and 5.1%) 
and FSH (4.9% and 3.5%). 
2.2.8. Statistical analysis:Data are shown as means ± SEM. The comparison of mean difference in 
the number of ovarian follicles, corpora lutea and degenerative cysts, levels of serum FSH and estradiol in 
the study groups was evaluated by using the ONE-WAY ANOVA test of variance, followed by Bonferroni 
post hoc test. The difference was regarded as statistically significant if the P value was < 0.05. Statistical 
analysis was done with statistical package of social science (SPSS) computer software version 20 and data 
were presented in the form of tables and figures. 
3. Results 
3.1. Human umbilical cord blood hematopoietic stem cells transplantation decreased the loss of ovarian follicles,   
significantly restored the  folliculogenesis and decreased cyst formation, edema and hemorrhage  in 
cyclophosphamide-induced ovarian dysfunction:The number of ovarian follicles was significantly decreased in group 
(2) vs. group 1. HUCBCD34+ cells transplantation in group (3) decreased this loss in ovarian follicles and there was no 
significant difference between group (3) and group (1) in the number of ovarian follicles (Figure1). The number of 
corpora lutea was significantly higher in group (3) vs. group (2) and it was not significantly different vs. group (1) (table 
1) so HUCBCD34+ cells transplantation restored folliculogenesis in cyclophosphamide-induced ovarian dysfunction. The 
number of degenerative cysts was significantly increased in group (2) vs. group (1) and  HUCBCD34+ cells 
transplantation decreased the number of degenerative cysts to reach a statistically non-significant difference  vs. group 
(1) (table 1).Histopathological examination of ovarian sections from group (1) showed normal ovarian tissue with normal 
follicles at different stages of maturation (figure 2). In group (2)histopathological examination showed decreased number 
of follicles and corpora lutea, increased the number of degenerative cysts, edematous tissues and hemorrhage (figure 3). 
These previous changes were significantly ameliorated after HUCBCD34+ cells transplantation in group (3) (figure 4).   
3.2. HUCB CD34+ cells transplantation had no significant effect on serum hormonal changes caused by 
cyclophosphamide-induced ovarian dysfunction:The serum level of FSH was significantly increased in groups (2) and 
(3) vs. group (1) (10.13 ± 0.3 and 10.037 ± 0.2 vs. 5.3 ± 0.5, P < 0.05) (table 2).Cyclophosphamide 
injectionssignificantly increased serum estradiol level in group (2) vs. group (1). HUCB CD34+ cells transplantation 
didn't change this finding and serum estradiol level was significantly higher in group (3) vs. group (1). There was no 
significant difference in serum FSH level or serum estradiol level in group (2) vs. group (3) (table 2). 
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Figure 1: Comparison of ovarian   follicles mean number in the study groups. 
*significant difference in the mean number of the ovarian follicles between group (1) vs. group (2) (P = 0.047). 
 
 
Table 1: Comparison in the number of corpora lutea and ovarian cysts among the studied groups at the end of the study 
 Group (1) Group (2) Group (3) 
Corpora lutea 
 (Mean ± SEM) 
7.7 ± 0.9 *a 2.7 ± 0.3 6.6 ± 0.4 
Ovarian cysts 
(Mean ± SEM) 
0.5 ± 0.5 *b 5.3 ± 2.2 1.1 ± 0.5 
 
*a  significant difference in the mean number of the corpora lutea between group (2) vs. groups (1) and (3) (P < 
0.05). 
*b significant difference in the mean number of the ovarian cysts between group (2) vs.group(1) (P < 0.05). 
Table 2:  Comparison in serum FSH mean levels and serum estradiol mean levels among   the studied groups at the end 
of the study 
 Group (1) Group (2) Group (3) 
Serum FSH (mIU /ml) 
Mean ± SEM 
*5.3 ± 0.5 10.13 ± 0.3 10.037 ± 0.2 
Serum estradiol (Pg/ml) 
Mean ± SEM 
* 48.4 ± 10 145 ± 13 120.5  ± 12 
*significant difference in the mean levels of serum FSH and serum estradiol levels in group (1) vs.  groups(2) and (3). 
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Figure 2:  A Photomicrograph of a section in the ovary of group (1) showing normal ovarian follicles at different stages 
of maturation. H&E x10. 
 
 
 
 
 
 
 
Figure 3:  A Photomicrograph of a section in the ovary of group (2) showed decreased number of follicles, decreased 
number of corpora lutea, increased number of degenerative cysts, edema and hemorrhage. H&E X10. 
 
Figure 4:  A Photomicrograph of a section in the ovary of group (3)showed  increased number of follicles, corpora lutea 
and absence of degenerative cysts, edema and hemorrhage. H&E x10. 
 
Hemorrhage 
 
Edema 
Cyst 
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3. Discussion 
In the current study the repeated administration of cyclophosphamide resulted in a significant decrease   in the number of 
ovarian follicles and corpora   lutea, a significant increase in the degenerative cyst formation and caused edema and 
hemorrhage. These findings were ameliorated after HUCB hematopoietic CD34+ cells transplantation. HUCB 
hematopoietic CD34+ cells decrease the loss of ovarian follicles induced by cyclophosphamide and improved 
folliculogenesis. These findings are in agreement with other investigators who proved that intravenously injected bone 
marrow stem cells restored follicular maturation in mice having a mutation in FSH receptor gene leading to elevated 
FSH, decreased estrogen levels, and sterility because of the absence of folliculogenesis [15]. Another study reported that 
ovarian activity, both hormonally and folliculogenesis, were restored after incorporation of mesenchymal stem cells 
derived from rats bone marrow into the ovarian stroma following cyclophosphamide-induced ovarian failure in rats [14]. 
Takehara et al. evaluated the effects on ovarian function after the transplantation of rat adipose tissue-mesenchymal stem 
cells into ovaries in rats with ovarian failure induced by cyclophosphamide. They reported that the transplantation of 
adipose tissue-mesenchymal stem cells resulted in an increased counts of corpora lutea and ovarian follicles [16]. 
The mechanism of this improvement after stem cells transplantation is controversial.  In their study of the therapeutic 
potential of umbilical cord mesenchymal stem cells (UCMSCs) in mice premature ovarian failure induced by 
cyclophosphamide, authors reported that the UCMSCsdidn't differentiate into follicles and they attributed the 
improvement in ovarian function to the ability of UCMSCs to reduce apoptosis of the granulosa cells and that UCMSCs 
function primarily by reactivating host oogenesis [1].On the other hand another study reported that the return of ovarian 
activity after cyclophosphamide administration was the result of incorporation of the stem cells within the ovarian tissue 
with transformation into the proposed cells and authors supported this suggestion by finding (Sry) gene (derived from 
male rats stem cells) within the ovarian tissue in female rats included in their study [14].Another mechanism may be  
involved is that stem cells secrete high levels of vascular endothelial cell growth factor, insulin-like growth factor-1 and 
hepatocyte growth factor which are known to affect follicular growth in ovaries [16].Abd-Allah and her colleagues 
concluded that mesenchymal stem cells improved ovarian function   by direct differentiation into specific cellular 
phenotypes and by secretion of vascular endothelial cell growth factor, which influence the regeneration of the ovary 
[17]. 
Another finding in this study was that HUCB hematopoietic CD34+ cells transplantation causes no significant difference 
in serum FSH level or serum estradiol level when compared with cyclophosphamide -treated group. This finding was in 
contrast to other studies which concluded that stem cells transplantation improves folliculogenesis, decreases serum FSH 
level and increases serum estradiol level [14,15].The absence of this effect  in the current study  may be explained by 
using different type and source of the stem cells. In the current study, hematopoieticCD34+ stem cells from human 
umbilical cord blood were used while other studies used mesenchymal stem cells from the rat bone marrow.     
It was interesting that doses of cyclophosphamide which resulted in a significant decrease in the number of ovarian 
follicles and corpora   lutea, a significant increase in cyst formation, marked pathological changes with edema and 
hemorrhage and significant elevation in serum FSH level did not produce a reduction in the serum estradiol level but that 
doses of cyclophosphamide caused a significant  elevation in serum estradiol. This paradox raises two questions; the first 
question is how does the level of serum estradiol increase within these experimental conditions? And the second question 
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is why does not the increased level of serum estradiol inhibit FSH secretion within these experimental conditions? It 
appeared that the increased serum level of estradiol may be caused by a decrease in its excretion by the liver and the 
kidneys which could be affected by cyclophosphamide toxicity [18,19,20].“As a hormone’s concentration in the plasma 
depends upon (1) its rate of secretion by the endocrine gland, and (2) its rate of removal from the blood. Removal of the 
hormone occurs either by excretion or by metabolic transformation. The liver and the kidneys are the major organs that 
excrete or metabolize hormones”[21]. Another explanation may be involved here is peripheral conversion of excess 
androgens secreted by the residual ovarian interstitial and stromal tissue to estradiol by adipose tissue [22] or both 
defective excretion and increased production from peripheral conversion in adipose tissues were responsible for the rise 
of serum estradiol. 
The elevated level of serum FSH within these experimental conditions could be explained by positive feed-back effect of 
dramatically increased serum estradiol level or by loss of inhibin hormone secretion from cyclophosphamide-damaged 
ovarian follicles and consequently loss of negative feed-back inhibition effect of inhibin on FSH secretion[23] or 
endocrine dysfunction in hypothalamus-pituitary-ovarian Axis due to cyclophosphamide toxicity [24].Another 
possibility is that all these factors may contribute to elevate serum FSH level. 
4. Conclusion 
The current study suggests that transplantation of HUCB hematopoietic CD34+ cells into rats with cyclophosphamide-
induced ovarian dysfunction improved ovarian folliculogenesisfunction  with no significant effect on hormonal secretion 
function and further studies are required to clarify the role of stem cells transplantation as a cure for ovarian dysfunction. 
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